I am wondering what the forum members' opinions are regarding the potential of the Starpharma share price in 5-10 years if all or most of the current DEP/cancer drug studies eventually get FDA and EMA approval. I started investing in Starpharma several years ago when the stock was at $1.20 U.S. just based on the Vivagel technology. Now that they have branched out with their DEP technology in combination with various cancer drugs, it would seem to me that the potential sales of all these combo cancer drugs would be astronomical. But I wonder what percentage of the profits would go to Starpharma and what would go to the companies that own the underlying cancer drugs? Are we looking at a sleeping giant, with ten-bagger potential from the current price, or would Starpharma's percentage of the profits be so small as limit the eventual market capitalization of the stock? Hoping that someone with more knowledge than me has done an in-depth analysis.